Exercise News and Research

Latest Exercise News and Research

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

Weight loss competition to be held to bring a new focus on healthy living

WDIV-TV, Blue Cross Blue Shield of Michigan and The Parade Company will launch The Biggest Loser: Detroit Edition contest on Monday, August 31. Six contestants from Metro Detroit have been selected from approximately 200 applicants to compete in this 12-week weight loss challenge to be featured on ClickonDetroit.com.

29 Aug 2009

Ranaz Corporation to raise funds through private placement

Ranaz Corporation ("Ranaz") (TSXV: RNZ), a company specialized in the manufacturing and marketing of protein and dietary supplements, announces that it intends to raise $675,000 through a non-brokered private placement of units.

29 Aug 2009

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing.

29 Aug 2009

Researchers develop an index scale to help physicians predict a patient's risk of dying from COPD

Researchers have developed an index scale to help physicians predict a patient's risk of dying from chronic obstructive pulmonary disease (COPD). The ADO index can help physicians assess the severity of a patient's illness to determine the appropriate level of treatment. COPD, which comprises emphysema and chronic bronchitis, is a major public health problem and it is the fourth leading cause of death in the U.S. The study of the ADO index is published in the August 29 edition of the Lancet.

29 Aug 2009

Metiscan closes equity funding of $7.3M

Metiscan, Inc. (PINKSHEETS: MTIZ), a holding company focused on growing its organization by making key acquisitions and developing companies and emerging technologies, announced today that it has closed an equity funding of $7.3M, which has been deposited in a restricted cash account owned by Metiscan. Funds shall be distributed subject to a registration statement filed with the SEC becoming effective and other conditions outlined in an account management agreement. The investors also have the option to exercise warrants up to $10M.

28 Aug 2009

CNS Response raises funds through private placement for general corporate purposes

CNS Response, Inc. (OTCBB: CNSO) (the "Company") today announced that it has completed a closing of its private placement, resulting in gross proceeds to the Company of approximately $2,000,000.

28 Aug 2009

Genvec to sell 8,000,000 shares to develop its TNFerade clinical program

GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a purchase agreement with a single institutional investor for the sale of 8,000,000 shares of its common stock and warrants to purchase 4,000,000 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.50 warrants to purchase one share of common stock at a price of $0.75 per unit. This represents a discount of approximately 8.3% to the closing price of GenVec common stock on August 26, 2009. The warrants have a term of five years and an exercise price of $0.828 per share.

28 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

The Research Partnership study reveals that diabetes can have a major effect on people's lives

A new research study carried out by The Research Partnership reveals that living with diabetes can have a major effect on people's lives, with just under half (44%) of type 2 patients reporting that the condition has impacted on either their ability or their desire to have sex.

28 Aug 2009

NIH panel releases report on the pertinence of family health history information in improving health

Though most Americans are familiar with completing a questionnaire about their family health history when visiting health care providers, an independent panel was convened by the National Institutes of Health this week to critically assess exactly what we know and what we need to learn about how this process relates to improving health.

28 Aug 2009

Alimera Sciences' $5 million extension of Series C financing closed

Alimera Sciences, Inc., today announced that it has closed a $5 million extension of its Series C financing which was originally completed in March 2008.

28 Aug 2009

AAPS and CURE file a free speech lawsuit against the White House

The Office of the President and other White House officials are defendants in a free speech lawsuit filed by a prominent physician group, and a non-profit advocate for inner-city poor.

28 Aug 2009

New risk index for COPD developed to estimate the risk of death

Researchers from the Centre for Research in Environmental Epidemiology (CREAL) and the Municipal Institute of Medical Research (IMIM-Hospital del Mar), in collaboration with the Hospital Clínic of Barcelona, have participated in an international consortium that has developed a new risk index for COPD patients. With this index, doctors can assess disease severity more objectively and estimate the risk of death.

28 Aug 2009

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the dosing of the first patient in a Phase I clinical study of AR-12 (formerly OSU-03012) in adult patients with advanced or recurrent solid tumors or lymphoma.

28 Aug 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Department of Veterans Affairs cancels contract with UTSWMC for Gulf War research

Citing persistent noncompliance and numerous performance deficiencies, the Department of Veterans Affairs (VA) will not exercise the third year of a five-year, $75 million contract with the University of Texas Southwestern Medical Center (UTSWMC) to perform research into Gulf War Veterans' Illnesses (GWVI).

27 Aug 2009

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Exercise News and Research

Latest Exercise News and Research

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Weight loss competition to be held to bring a new focus on healthy living

Ranaz Corporation to raise funds through private placement

Inhibitor Education Summits to address pertinent topics regarding hemophilia

Researchers develop an index scale to help physicians predict a patient's risk of dying from COPD

Metiscan closes equity funding of $7.3M

CNS Response raises funds through private placement for general corporate purposes

Genvec to sell 8,000,000 shares to develop its TNFerade clinical program

Thrombogenics issues business update and half year results

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

The Research Partnership study reveals that diabetes can have a major effect on people's lives

NIH panel releases report on the pertinence of family health history information in improving health

Alimera Sciences' $5 million extension of Series C financing closed

AAPS and CURE file a free speech lawsuit against the White House

New risk index for COPD developed to estimate the risk of death

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Department of Veterans Affairs cancels contract with UTSWMC for Gulf War research

Alexza completes acquisition of Symphony Allegro after sharholders' approval

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Exercise News and Research

Latest Exercise News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in